# Allogene Therapeutics, Inc. (ALLO) · Edgar & Edgarette company card

> Allogene Therapeutics (ALLO) saw revenue fall 100% in FY2025 to $0 million, operating margin null against a -15.8% median for biological products, (no diagnostic substances), equity 70.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1737287 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ALLO) · [JSON](https://www.pops4.com/boards/company/ALLO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -1241813.6%) |
| Net margin | -Infinity% |
| Operating cash flow | −$149M |
| Capital spending | $386,000 |
| Free cash flow | −$150M |
| Cash | $52M |
| Long-term debt | — |
| Total assets | $416M |
| Total equity | $293M |
| Equity ÷ assets | 70.3% |
| Return on equity | -65.3% |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: -13.1 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$149.2M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: revenue down 100.0% on the year; operating margin null, down from -1241813.6%. Soundness: equity 70.3% of assets, return on equity -65.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin null against a -15.8% median; growth -100.0% against 21.4%.

Range logged 2026-09-20, receipt 7dcda61e422499a9, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1737287/000119312526379423/0001193125-26-379423-index.htm))

## Recent filings

- 8-K · filed 2026-09-02 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1737287/000119312526379423/0001193125-26-379423-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/0001628280-26-056213-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/0001628280-26-056198-index.htm)
- 8-K · filed 2026-06-22 · 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1737287/000162828026044618/0001628280-26-044618-index.htm)
- 8-K · filed 2026-05-28 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm)
- 10-Q · filed 2026-05-13 · [filing](https://www.sec.gov/Archives/edgar/data/1737287/000162828026034585/0001628280-26-034585-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001737287.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1737287

## Cite

POPS4, Edgar & Edgarette: Allogene Therapeutics, Inc. (ALLO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ALLO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.